OptimizeRx Corp (NASDAQ:OPRX) has a beta value of 1.30 and has seen 0.19 million shares traded in the last trading session. The company, currently valued at $122.31M, closed the last trade at $6.64 per share which meant it gained $0.35 on the day or 5.56% during that session. The OPRX stock price is -150.75% off its 52-week high price of $16.65 and 43.07% above the 52-week low of $3.78. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.12 million shares traded. The 3-month trading volume is 285.65K shares.
The consensus among analysts is that OptimizeRx Corp (OPRX) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.27.
OptimizeRx Corp (NASDAQ:OPRX) trade information
Sporting 5.56% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OPRX stock price touched $6.64 or saw a rise of 0.75%. Year-to-date, OptimizeRx Corp shares have moved 36.63%, while the 5-day performance has seen it change 20.29%. Over the past 30 days, the shares of OptimizeRx Corp (NASDAQ:OPRX) have changed 34.41%. Short interest in the company has seen 1.28 million shares shorted with days to cover at 7.5.
Wall Street analysts have a consensus price target for the stock at $15, which means that the shares’ value could jump 55.73% from current levels. The projected low price target is $15.0 while the price target rests at a high of $15.0. In that case, then, we find that the current price level is -125.9% off the targeted high while a plunge would see the stock gain -125.9% from current levels.
OptimizeRx Corp (OPRX) estimates and forecasts
The company’s shares have lost -20.57% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 26.07%.
8 analysts offering their estimates for the company have set an average revenue estimate of 30.36M for the current quarter. 5 have an estimated revenue figure of 21.26M for the next ending quarter. Year-ago sales stood 28.37M and 19.69M respectively for this quarter and the next, and analysts expect sales will grow by 7.01% for the current quarter and 26.07% for the next.
Earnings growth for 2025 is a modest 18.74% while over the next 5 years, the company’s earnings are expected to increase by 22.67%.
OPRX Dividends
OptimizeRx Corp is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
OptimizeRx Corp (NASDAQ:OPRX)’s Major holders
Insiders own 14.26% of the company shares, while shares held by institutions stand at 68.41% with a share float percentage of 79.78%. Investors are also buoyed by the number of investors in a company, with OptimizeRx Corp having a total of 132.0 institutions that hold shares in the company. The top two institutional holders are FIRST LIGHT ASSET MANAGEMENT, LLC with over 1.83 million shares worth more than $18.27 million. As of 2024-06-30, FIRST LIGHT ASSET MANAGEMENT, LLC held 10.0548% of shares outstanding.
The other major institutional holder is DIVISADERO STREET CAPITAL MANAGEMENT, LP, with the holding of over 1.32 million shares as of 2024-06-30. The firm’s total holdings are worth over $13.16 million and represent 7.2422% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Jacob Internet Fund. As of Sep 30, 2024, the former fund manager holds about 4.19% shares in the company for having 506.69 shares of worth $3.36 million while later fund manager owns 497.88 shares of worth $3.31 million as of Nov 30, 2024, which makes it owner of about 4.12% of company’s outstanding stock.
